Nasus Pharma
NSRX
9 hedge funds and large institutions have $4.83M invested in Nasus Pharma in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
22,082% more capital invested
Capital invested by funds: $21.8K → $4.83M (+$4.8M)
350% more funds holding
Funds holding: 2 → 9 (+7)
18.57% more ownership
Funds ownership: 0% → 18.57% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.64M |
| 2 |
CCC
Cable Car Capital
San Francisco,
California
|
+$3.11M |
| 3 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
+$1.86M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$696K |
| 5 |
BL
Bleichroeder LP
New York
|
+$464K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Balyasny Asset Management
Chicago,
Illinois
| $1.99M | +$4.64M | +898,473 | New |
|
|
CCC
2
Cable Car Capital
San Francisco,
California
| $1.34M | +$3.11M | +601,998 | New |
|
|
VCIM
3
Velan Capital Investment Management
Alpharetta,
Georgia
| $798K | +$1.86M | +359,390 | New |
|
|
4
Hudson Bay Capital Management
Stamford,
Connecticut
| $299K | +$696K | +134,771 | New |
|
|
BL
5
Bleichroeder LP
New York
| $199K | +$464K | +89,848 | New |
|
|
EAM
6
Empery Asset Management
New York
| $102K | +$236K | +45,803 | New |
|
|
HF
7
HRT Financial
New York
| $86K | +$201K | +38,897 | New |
|
8
UBS Group
Zurich,
Switzerland
| $6.87K | +$14K | +2,716 | +719% |
|
9
Morgan Stanley
New York
| $4.44K | – | – | – |
|
NSRX Hedge Fund Activity: Q1 2026 in Review
9 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Nasus Pharma (NSRX) for Q1 2026, worth a combined $4.83M — up 22,082% from $21.8K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NSRX positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $4.64M.
- 9 institutional investors held Nasus Pharma (NSRX) as of Q1 2026, up from 2 in Q4 2025.
- Funds reported $4.83M of Nasus Pharma stock for Q1 2026, up 22,082% quarter-over-quarter.
- 7 funds opened new Nasus Pharma positions in Q1 2026 and 0 closed out, a net change of +7 holders.
- The largest Nasus Pharma buyer in Q1 2026 was Balyasny Asset Management, an estimated $4.64M added.
Based on aggregated 13F filings for Q1 2026.